Paper33569332
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival.
Casal-Mouriño A and 9 others. Transl Lung Cancer Res, 2021. Cited by 156 papers, by iCite.
Cite this record
ConductScience Library. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Papers, record 33569332. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33569332
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18378568 | Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18378568 | PubMed |
| 2 | 9241071 | Risk of squamous cell carcinoma and adenocarcinoma of the lung in relation to lifetime filter cigarette smoking. | Cancer | 1997 | https://conductscience.org/library/papers/9241071 | PubMed |
| 3 | 31591865 | Chemoradiotherapy versus radiotherapy alone following induction chemotherapy for elderly patients with stage III lung cancer. | Radiat Oncol J | 2019 | https://conductscience.org/library/papers/31591865 | PubMed |
| 4 | 31514942 | Stage III Non-small Cell Lung Cancer Management in England. | Clin Oncol (R Coll Radiol) | 2019 | https://conductscience.org/library/papers/31514942 | PubMed |
| 5 | 30175515 | Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. | Cancer Med | 2018 | https://conductscience.org/library/papers/30175515 | PubMed |
| 6 | 25422491 | Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25422491 | PubMed |
| 7 | 28140453 | Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. | CA Cancer J Clin | 2017 | https://conductscience.org/library/papers/28140453 | PubMed |
| 9 | 22617240 | Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada. | J Thorac Oncol | 2012 | https://conductscience.org/library/papers/22617240 | PubMed |
| 10 | 25846096 | Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/25846096 | PubMed |
| 11 | 31519618 | Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment. | Anticancer Res | 2019 | https://conductscience.org/library/papers/31519618 | PubMed |
| 12 | 28885881 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28885881 | PubMed |
| 13 | 29666219 | Symptoms at lung cancer diagnosis are associated with major differences in prognosis. | Thorax | 2018 | https://conductscience.org/library/papers/29666219 | PubMed |
| 14 | 18538025 | Environment And Genetics in Lung cancer Etiology (EAGLE) study: an integrative population-based case-control study of lung cancer. | BMC Public Health | 2008 | https://conductscience.org/library/papers/18538025 | PubMed |
| 15 | 24419411 | A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). | J Thorac Oncol | 2014 | https://conductscience.org/library/papers/24419411 | PubMed |
| 16 | 28881918 | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Ann Oncol | 2017 | https://conductscience.org/library/papers/28881918 | PubMed |
| 17 | 26711663 | Is Lung Cancer Incidence Increasing in Never-Smokers? | J Natl Cancer Inst | 2016 | https://conductscience.org/library/papers/26711663 | PubMed |
| 18 | 24498478 | Survival after Pneumonectomy for Stage III Non-small Cell Lung Cancer. | Oman Med J | 2014 | https://conductscience.org/library/papers/24498478 | PubMed |
| 19 | 30630993 | Non-Small Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia. | Acta Med Indones | 2018 | https://conductscience.org/library/papers/30630993 | PubMed |
| 20 | 11165392 | Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. | Lung Cancer | 2001 | https://conductscience.org/library/papers/11165392 | PubMed |
| 21 | 28625632 | A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer. | Lung Cancer | 2017 | https://conductscience.org/library/papers/28625632 | PubMed |
Cited by108
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 156 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42959795 | Pancreatic involvement in lung cancer: Imaging findings and diagnostic challenges in two cases. | Radiol Case Rep | 2026 | https://conductscience.org/library/papers/42959795 | PubMed |
| 42865845 | Real-world survival outcomes following multimodal surgical treatment for stage IIIA non-small cell lung cancer. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42865845 | PubMed |
| 42859818 | Comparative Evaluation of Concurrent Carboplatin-Paclitaxel Versus Cisplatin-Etoposide Chemoradiotherapy in Unresectable Non-small Cell Lung Cancer: A Prospective Randomized Study. | Cureus | 2026 | https://conductscience.org/library/papers/42859818 | PubMed |
| 42648750 | AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42648750 | PubMed |
| 42528479 | Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience. | Future Oncol | 2026 | https://conductscience.org/library/papers/42528479 | PubMed |
| 42516805 | A three-gene signature correlated with MAPK/ERK activation characterizes acquired resistance to EGFR-tyrosine kinase inhibitors in non-small cell lung cancer. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42516805 | PubMed |
| 42512379 | Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315). | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512379 | PubMed |
| 42499789 | Clinical management and outcomes of relapsed NSCLC after chemoradiotherapy and durvalumab consolidation: real-world evidence from Germany. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/42499789 | PubMed |
| 42475143 | Guideline concordance of stage IIIA non-small-cell lung cancer treatment in the Australian setting. | Intern Med J | 2026 | https://conductscience.org/library/papers/42475143 | PubMed |
| 42440255 | Pharmacogenomics in oncology: mutation-targeted therapy and biomarker integration in non-small cell lung cancer. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/42440255 | PubMed |
| 42434745 | Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis. | Front Oncol | 2026 | https://conductscience.org/library/papers/42434745 | PubMed |
| 42366611 | European Cancer Prevention Organization on cancer screening: an expert panel position paper. | Eur J Cancer Prev | 2026 | https://conductscience.org/library/papers/42366611 | PubMed |
| 42351059 | Distribution and rate of lymph node metastasis following neoadjuvant chemoimmunotherapy in non-small cell lung cancer. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42351059 | PubMed |
| 42294336 | Understanding cardiac toxicity and immune responses to thoracic radiation therapy in non-small cell lung cancer - implications for future research. | Front Oncol | 2026 | https://conductscience.org/library/papers/42294336 | PubMed |
| 42249675 | Stage III Non-small Cell Lung Cancer Resectability in a Country With Limited Diagnostic and Therapeutic Resources: A Colombian Expert Consensus. | Cancer Control | 2026 | https://conductscience.org/library/papers/42249675 | PubMed |
| 42152809 | Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study. | Thorac Cancer | 2026 | https://conductscience.org/library/papers/42152809 | PubMed |
| 42093990 | Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of in vivo CAR-T platforms. | Front Immunol | 2026 | https://conductscience.org/library/papers/42093990 | PubMed |
| 42070217 | Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA Study. | Target Oncol | 2026 | https://conductscience.org/library/papers/42070217 | PubMed |
| 41975140 | Management of borderline resectable NSCLC: a narrative review. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41975140 | PubMed |
| 41945947 | The Prognostic Impact of Supraclavicular Lymph Node Metastases in Lung Cancer: Do We Need a Modification of the Current Staging System? | Asian Pac J Cancer Prev | 2026 | https://conductscience.org/library/papers/41945947 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALK | 238 | PubTator's text mining | https://conductscience.org/library/genes/238 | NCBI Gene |
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| KRAS | 3845 | PubTator's text mining | https://conductscience.org/library/genes/3845 | NCBI Gene |
| MET | 4233 | PubTator's text mining | https://conductscience.org/library/genes/4233 | NCBI Gene |
| RET | 5979 | PubTator's text mining | https://conductscience.org/library/genes/5979 | NCBI Gene |
| ROS1 | 6098 | PubTator's text mining | https://conductscience.org/library/genes/6098 | NCBI Gene |
| SLTM | 79811 | PubTator's text mining | https://conductscience.org/library/genes/79811 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33569332
GET https://conductscience.org/api/papers/v1/33569332/references?page=2